Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

46.7%

7 terminated out of 15 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed with results

Key Signals

4 with results50% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (5)
Early P 1 (2)
P 1 (6)
P 2 (2)

Trial Status

Completed7
Terminated7
Withdrawn1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT01165632Early Phase 1Completed

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT02186509Phase 1Completed

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT01478321Phase 2Terminated

Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

NCT01234805Not ApplicableTerminated

Yoga Therapy in Treating Patients With Malignant Brain Tumors

NCT01234740Phase 1Completed

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

NCT02194452Not ApplicableWithdrawn

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

NCT01996527Early Phase 1Terminated

3T MRI Biomarkers of Glioma Treatment Response

NCT02967380Not ApplicableTerminated

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02175745Not ApplicableTerminatedPrimary

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT01119599Phase 1Completed

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

NCT01131234Phase 1Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT00492089Phase 2Completed

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00110032Phase 1Terminated

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

NCT00030498Phase 1Completed

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

NCT00430079Not ApplicableTerminated

Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma

Showing all 15 trials

Research Network

Activity Timeline